We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

104 hedge funds and large institutions have $138M invested in VYNE Therapeutics in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 23 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 23

5% more capital invested

Capital invested by funds: $132M → $138M (+$6.25M)

0.07% more ownership

Funds ownership: 0.66% → 0.73% (+0.07%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less funds holding

Funds holding: 105 → 104 (-1)

5% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 19

Holders
104
Holders Change
-1
Holders Change %
-0.95%
% of All Funds
1.84%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
18
Increased
37
Reduced
23
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.74M
2
DAM
Deltec Asset Management
New York
+$3.66M
3
Two Sigma Investments
Two Sigma Investments
New York
+$1.05M
4
Squarepoint
Squarepoint
New York
+$874K
5
State Street
State Street
Massachusetts
+$866K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$1.54M
2
MIM
Monashee Investment Management
Massachusetts
-$581K
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$352K
4
Morgan Stanley
Morgan Stanley
New York
-$277K
5
SSA
Schonfeld Strategic Advisors
New York
-$256K
Name Holding Trade Value Shares
Change 		Change in
Stake
Victory Capital Management
76
Victory Capital Management
Texas
$36K -$251 -2 -0.6%
WC
77
Wexford Capital
Florida
$35K +$38.2K +304 New
First Manhattan
78
First Manhattan
New York
$33K -$5.28K -42 -12%
BWA
79
BDO Wealth Advisors
Florida
$32K – – –
Royal Bank of Canada
80
Royal Bank of Canada
Ontario, Canada
$30K +$24K +191 +273%
PAG
81
Private Advisor Group
New Jersey
$28K – – –
GC
82
Grace Capital
Massachusetts
$28K +$31.4K +250 New
SPIA
83
Steward Partners Investment Advisory
New York
$27K -$9.05K -72 -23%
HSBC Holdings
84
HSBC Holdings
United Kingdom
$26K +$6.03K +48 +26%
EGM
85
Engineers Gate Manager
New York
$26K +$9.93K +79 +54%
WMP
86
Wealth Management Partners
Arizona
$25K +$17.5K +139 New
RC
87
RegentAtlantic Capital
New Jersey
$24K – – –
TFA
88
Tobias Financial Advisors
Florida
$23K – – –
Legal & General Group
89
Legal & General Group
United Kingdom
$20K – – –
NIM
90
NXG Investment Management
Texas
$19K +$3.9K +31 +22%
TWA
91
TCI Wealth Advisors
Arizona
$18K – – –
AB
92
Amalgamated Bank
New York
$16K – – –
AIP
93
Ameritas Investment Partners
Nebraska
$15K – – –
HF
94
HRT Financial
New York
$15K +$17.6K +140 New
PCM
95
Penserra Capital Management
California
$6K +$6.66K +53 New
Osaic Holdings
96
Osaic Holdings
Arizona
$3K – – –
Nisa Investment Advisors
97
Nisa Investment Advisors
Missouri
$3K +$2.01K +16 +133%
IA
98
IFP Advisors
Florida
$2K +$1.76K +14 +700%
CCM
99
Cribstone Capital Management
Maine
$1K – – –
EWM
100
Edge Wealth Management
New York
$1K – – –
1 2 3
4
5

VYNE Hedge Fund Activity: Q4 2020 in Review

104 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2020, worth a combined $138M — up 4.7% from $132M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of VYNE and 18 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 37 added.

The largest buyer was BlackRock, adding an estimated $3.74M. The largest seller was Vivo Capital, cutting an estimated $1.54M.

  • 104 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2020, down from 105 in Q3 2020.
  • Funds reported $138M of VYNE Therapeutics stock for Q4 2020, up 4.7% quarter-over-quarter.
  • 18 funds opened new VYNE Therapeutics positions in Q4 2020 and 19 closed out, a net change of -1 holder.
  • The largest VYNE Therapeutics buyer in Q4 2020 was BlackRock, an estimated $3.74M added.
  • The largest VYNE Therapeutics seller in Q4 2020 was Vivo Capital, an estimated $1.54M sold.

Based on aggregated 13F filings for Q4 2020.